Bladder cancer is a complex disease that poses high risks of morbidity and mortality, especially when not treated optimally. Hematuria is the most common presenting symptom in patients with bladder ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Prostate cancer researchers Urine cytology after an initial TURBT predicted risk for a second TURBT one month later. The following article features coverage from the American Urological Association ...

To reduce papillary tumor recurrence, optimized intravesical mitomycin C combined with fluorescence blue-light cystoscopy shows promise. Fluorescence blue-light cystoscopy along with optimized ...

This Practice Point commentary discusses the study by Denzinger et al. in which patients with high-grade T1 (HGT1) bladder cancer were treated by transurethral resection with either white-light ...

The BladderPath study showed mpMRI reduced TTCT by 45 days for MIBC patients, enhancing treatment efficiency without harming non-MIBC patients. Conducted in 17 UK hospitals, the study involved 143 ...

MILAN — Photodynamic diagnosis-guided transurethral resection of bladder tumors did not reduce recurrence rates of non–muscle-invasive bladder cancer (NMIBC) in the longer term compared with standard ...

After a diagnosis of urothelial cancer, doctors will assign a stage to the disease -- determining how deep the tumor has invaded into the bladder and whether there is any spread to the lymph nodes and ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay between first sign and diagnosis can mean the difference between a ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...